Abstract
This study investigates the effects of mefepronic acid (MA), a PPAR-α agonist, on hepatic metabolic functions and reproduction of postpartum dairy cows. Sixty Friesian cows were divided into Group A (administered 5g of MA IM, within 24 hrs after calving, on the 3rd and 5th day postpartum) and Group B (control). All the cows were blood sampled within 24 hrs of calving (Day 0), on Day 3, 5, 10, 15, 30, and 40 postpartum. On plasma, metabolic and biochemical parameters were determined. Liver biopsies were performed on Day 0, 15 and 30 for the evaluation of hepatic lipid and glycogen content. Reproductive parameters were also evaluated.
In Group A, blood HDL, glucose and cholesterol increased till the end of the study, in accordance with the histological results. PPAR-α immunopositive cells increased in liver slices of Group A, too. Reproductive parameters improved in Group A. This study highlights the beneficial effects of mefepronic acid on the hepatic metabolism and reproductive parameters of post-partum dairy cows.
Keywords: Dairy cow, fatty acids, lipid, liver metabolism, mefepronic acid, reproduction.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows
Volume: 14 Issue: 2
Author(s): Annalisa Rizzo, Carlo Gazza, Maddalena Mutinati, Salvatore Desantis, Sara Zizza, Giovanni D'Onghia, Gianfranco D'Onghia, Marianna Pantaleo and Raffaele L. Sciorsci
Affiliation:
Keywords: Dairy cow, fatty acids, lipid, liver metabolism, mefepronic acid, reproduction.
Abstract: This study investigates the effects of mefepronic acid (MA), a PPAR-α agonist, on hepatic metabolic functions and reproduction of postpartum dairy cows. Sixty Friesian cows were divided into Group A (administered 5g of MA IM, within 24 hrs after calving, on the 3rd and 5th day postpartum) and Group B (control). All the cows were blood sampled within 24 hrs of calving (Day 0), on Day 3, 5, 10, 15, 30, and 40 postpartum. On plasma, metabolic and biochemical parameters were determined. Liver biopsies were performed on Day 0, 15 and 30 for the evaluation of hepatic lipid and glycogen content. Reproductive parameters were also evaluated.
In Group A, blood HDL, glucose and cholesterol increased till the end of the study, in accordance with the histological results. PPAR-α immunopositive cells increased in liver slices of Group A, too. Reproductive parameters improved in Group A. This study highlights the beneficial effects of mefepronic acid on the hepatic metabolism and reproductive parameters of post-partum dairy cows.
Export Options
About this article
Cite this article as:
Rizzo Annalisa, Gazza Carlo, Mutinati Maddalena, Desantis Salvatore, Zizza Sara, D'Onghia Giovanni, D'Onghia Gianfranco, Pantaleo Marianna and Sciorsci L. Raffaele, Effects of Mefepronic Acid (2-Phenoxy-2-Methyl Propionic Acid) on Hepatic Metabolism and Reproductive Parameters in Postpartum Dairy Cows, Endocrine, Metabolic & Immune Disorders - Drug Targets 2014; 14 (2) . https://dx.doi.org/10.2174/1871530314666140223184913
DOI https://dx.doi.org/10.2174/1871530314666140223184913 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Significance of P2X7 Receptor Variants to Human Health and Disease
Recent Patents on DNA & Gene Sequences Lactose and Casein Cause Changes on Biomarkers of Oxidative Damage and Dysbiosis in an Experimental Model of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Targeting Apoptosis to Treat Multiple Sclerosis
Current Drug Discovery Technologies Purinergic Signalling: What is Missing and Needed Next? The Use of Transgenic Mice, Crystallographic Analysis and MicroRNA
CNS & Neurological Disorders - Drug Targets The Role of Aryl Hydrocarbon Receptor-Regulated Cytochrome P450 Enzymes in Glioma
Current Pharmaceutical Design Post Traumatic Lesion absence of β-Dystroglycan-Immunopositivity in Brain Vessels Coincides with the Glial Reaction and the Immunoreactivity of Vascular Laminin
Current Neurovascular Research Chronic Inflammatory Diseases: Progress and Prospect with Herbal Medicine
Current Pharmaceutical Design Peroxisome Proliferator-Activated Receptor Agonists as Potential Therapeutic Agents in Multiple Sclerosis
Mini-Reviews in Medicinal Chemistry The Medicinal Chemistry of Therapeutic Peptides: Recent Developments in Synthesis and Design Optimizations
Current Medicinal Chemistry Future Therapeutic Strategies in Inflammatory Cardiomyopathy: Insights from the Experimental Autoimmune Myocarditis Model
Cardiovascular & Hematological Disorders-Drug Targets Cytokines as Regulators of Atherosclerosis in Murine Models
Current Drug Targets The Use of Statins in Respiratory Diseases
Current Respiratory Medicine Reviews Leptin as a Novel Therapeutic Target for Immune Intervention
Current Drug Targets - Inflammation & Allergy Actively Targeted Nanoparticles for Drug Delivery to Tumor
Current Drug Metabolism Antiviral Treatment of Chikungunya Virus Infection
Infectious Disorders - Drug Targets Potential Application of Gene Therapy to X-Linked Agammaglobulinemia
Current Gene Therapy Autoimmune Channelopathies of the Nervous System
Current Neuropharmacology Highly Organized Nanostructures for Brain Drug Delivery - New Hope or Just a Fad?
CNS & Neurological Disorders - Drug Targets Dihydropyridine Receptor Blockade in the Treatment of Asthma
Recent Patents on Inflammation & Allergy Drug Discovery Microglial Senescence
CNS & Neurological Disorders - Drug Targets